Amniotics AB (OSTO:AMNI) Net Income From Continuing Operations : kr-3.59 Mil (TTM As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Amniotics AB's net income from continuing operations for the three months ended in Dec. 2023 was kr9.04 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was kr-3.59 Mil.

Amniotics AB Net Income From Continuing Operations Historical Data

The historical data trend for Amniotics AB's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amniotics AB Net Income From Continuing Operations Chart

Amniotics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

-10.43

-30.99

-53.62

-46.69

-29.07

Amniotics AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial										-16.42	-23.09	-6.60	-6.03	9.04

Amniotics AB Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3.59 Mil.

Amniotics AB (OSTO:AMNI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

66J:Germany

Address

Scheelevagen 2, Lund, SWE, 223 63

Website

https://www.amniotics.com

Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.